335 related articles for article (PubMed ID: 32350552)
21. miR-708-5p and miR-34c-5p are involved in nNOS regulation in dystrophic context.
Guilbaud M; Gentil C; Peccate C; Gargaun E; Holtzmann I; Gruszczynski C; Falcone S; Mamchaoui K; Ben Yaou R; Leturcq F; Jeanson-Leh L; Piétri-Rouxel F
Skelet Muscle; 2018 Apr; 8(1):15. PubMed ID: 29703249
[TBL] [Abstract][Full Text] [Related]
22. A novel high-throughput immunofluorescence analysis method for quantifying dystrophin intensity in entire transverse sections of Duchenne muscular dystrophy muscle biopsy samples.
Sardone V; Ellis M; Torelli S; Feng L; Chambers D; Eastwood D; Sewry C; Phadke R; Morgan JE; Muntoni F
PLoS One; 2018; 13(3):e0194540. PubMed ID: 29579078
[TBL] [Abstract][Full Text] [Related]
23. Direct Reprogramming of Human DMD Fibroblasts into Myotubes for In Vitro Evaluation of Antisense-Mediated Exon Skipping and Exons 45-55 Skipping Accompanied by Rescue of Dystrophin Expression.
Lee JJA; Saito T; Duddy W; Takeda S; Yokota T
Methods Mol Biol; 2018; 1828():141-150. PubMed ID: 30171539
[TBL] [Abstract][Full Text] [Related]
24. Systemic Delivery of Morpholinos to Skip Multiple Exons in a Dog Model of Duchenne Muscular Dystrophy.
Maruyama R; Echigoya Y; Caluseriu O; Aoki Y; Takeda S; Yokota T
Methods Mol Biol; 2017; 1565():201-213. PubMed ID: 28364245
[TBL] [Abstract][Full Text] [Related]
25. Duchenne and Becker muscular dystrophy: contribution of a molecular and immunohistochemical analysis in diagnosis in Morocco.
Bellayou H; Hamzi K; Rafai MA; Karkouri M; Slassi I; Azeddoug H; Nadifi S
J Biomed Biotechnol; 2009; 2009():325210. PubMed ID: 19461958
[TBL] [Abstract][Full Text] [Related]
26. The AAV-mediated and RNA-guided CRISPR/Cas9 system for gene therapy of DMD and BMD.
Wang JZ; Wu P; Shi ZM; Xu YL; Liu ZJ
Brain Dev; 2017 Aug; 39(7):547-556. PubMed ID: 28390761
[TBL] [Abstract][Full Text] [Related]
27. Patients with Duchenne muscular dystrophy are significantly shorter than those with Becker muscular dystrophy, with the higher incidence of short stature in Dp71 mutated subgroup.
Matsumoto M; Awano H; Lee T; Takeshima Y; Matsuo M; Iijima K
Neuromuscul Disord; 2017 Nov; 27(11):1023-1028. PubMed ID: 28734761
[TBL] [Abstract][Full Text] [Related]
28. Dystrophin quantification and clinical correlations in Becker muscular dystrophy: implications for clinical trials.
Anthony K; Cirak S; Torelli S; Tasca G; Feng L; Arechavala-Gomeza V; Armaroli A; Guglieri M; Straathof CS; Verschuuren JJ; Aartsma-Rus A; Helderman-van den Enden P; Bushby K; Straub V; Sewry C; Ferlini A; Ricci E; Morgan JE; Muntoni F
Brain; 2011 Dec; 134(Pt 12):3547-59. PubMed ID: 22102647
[TBL] [Abstract][Full Text] [Related]
29. Genetic polymorphism in muscle biopsies of Duchenne and Becker muscular dystrophy patients.
Anand A; Prabhakar S; Kaul D
Neurol India; 1999 Sep; 47(3):218-23. PubMed ID: 10514583
[TBL] [Abstract][Full Text] [Related]
30. Optimizing exon skipping therapies for DMD.
Yokota T; Duddy W; Partridge T
Acta Myol; 2007 Dec; 26(3):179-84. PubMed ID: 18646569
[TBL] [Abstract][Full Text] [Related]
31. Therapeutic strategies for Duchenne and Becker dystrophies.
Voisin V; de la Porte S
Int Rev Cytol; 2004; 240():1-30. PubMed ID: 15548414
[TBL] [Abstract][Full Text] [Related]
32. Systemic AAV Micro-dystrophin Gene Therapy for Duchenne Muscular Dystrophy.
Duan D
Mol Ther; 2018 Oct; 26(10):2337-2356. PubMed ID: 30093306
[TBL] [Abstract][Full Text] [Related]
33. Mutation spectrum analysis of Duchenne/Becker muscular dystrophy in 68 families in Kuwait: The era of personalized medicine.
Mohammed F; Elshafey A; Al-Balool H; Alaboud H; Al Ben Ali M; Baqer A; Bastaki L
PLoS One; 2018; 13(5):e0197205. PubMed ID: 29847600
[TBL] [Abstract][Full Text] [Related]
34. Duchenne and Becker muscular dystrophy: a molecular and immunohistochemical approach.
Freund AA; Scola RH; Arndt RC; Lorenzoni PJ; Kay CK; Werneck LC
Arq Neuropsiquiatr; 2007 Mar; 65(1):73-6. PubMed ID: 17420831
[TBL] [Abstract][Full Text] [Related]
35. Mdx mice inducibly expressing dystrophin provide insights into the potential of gene therapy for duchenne muscular dystrophy.
Ahmad A; Brinson M; Hodges BL; Chamberlain JS; Amalfitano A
Hum Mol Genet; 2000 Oct; 9(17):2507-15. PubMed ID: 11030755
[TBL] [Abstract][Full Text] [Related]
36. Designing Effective Antisense Oligonucleotides for Exon Skipping.
Shimo T; Maruyama R; Yokota T
Methods Mol Biol; 2018; 1687():143-155. PubMed ID: 29067661
[TBL] [Abstract][Full Text] [Related]
37. Functional significance of gain-of-function H19 lncRNA in skeletal muscle differentiation and anti-obesity effects.
Li Y; Zhang Y; Hu Q; Egranov SD; Xing Z; Zhang Z; Liang K; Ye Y; Pan Y; Chatterjee SS; Mistretta B; Nguyen TK; Hawke DH; Gunaratne PH; Hung MC; Han L; Yang L; Lin C
Genome Med; 2021 Aug; 13(1):137. PubMed ID: 34454586
[TBL] [Abstract][Full Text] [Related]
38. Exon deletion patterns of the dystrophin gene in 82 Vietnamese Duchenne/Becker muscular dystrophy patients.
Tran VK; Ta VT; Vu DC; Nguyen ST; Do HN; Ta MH; Tran TH; Matsuo M
J Neurogenet; 2013 Dec; 27(4):170-5. PubMed ID: 24099565
[TBL] [Abstract][Full Text] [Related]
39. [Mutation-specific treatments for Duchenne muscular dystrophy].
Matsuo M; Takeshima Y
Brain Nerve; 2009 Aug; 61(8):915-22. PubMed ID: 19697880
[TBL] [Abstract][Full Text] [Related]
40. Exons 45-55 Skipping Using Antisense Oligonucleotides in Immortalized Human DMD Muscle Cells.
He M; Yokota T
Methods Mol Biol; 2023; 2640():313-325. PubMed ID: 36995604
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
